Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10)

1. A method for treating pancreatic cancer in a human, comprising: intravenously administering Coenzyme Q10 (CoQ10) to the human at a dose of at least 5 mg/kg such that treatment occurs, wherein the CoQ10 is in its oxidized form and has a purity between 95% and 100%, and wherein administration of the CoQ10 to the human results in an increase of CoQ10 in the oxidized form in the human.

2. The method of claim 1 , wherein the treatment occurs via an interaction of Coenzyme Q10 with a protein selected from the group consisting of HNF4-alpha, Bcl-xl, Bcl-xS, BNIP-2, Bcl-2, Birc6, Bcl-2-L11 (Bim), XIAP, BRAF, Bax, c-Jun, Bmf, PUMA, cMyc, transaldolase 1, COQ1, COQ3, COQ6, prenyltransferase, 4-hydrobenzoate, neutrophil cytosolic factor 2, nitric oxide synthase 2A, superoxide dismutase 2, VDAC, Bax channel, ANT, Cytochrome c, complex 1, complex II, complex III, complex IV, Foxo 3a, DJ-1, IDH-1, Cpt1C, and Cam Kinase II and any one or more of genes listed in Tables 2-4 & 6-28.

3. The method of claim 1 , further comprising a treatment regimen selected from the group consisting of surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, and chemotherapy.

4. The method of claim 1 , wherein the Coenzyme Q10 is administered with an additional therapeutic agent.

5. The method of claim 4 , wherein the Coenzyme Q10 is administered concurrently with the additional therapeutic agent.

6. The method of claim 4 , wherein the Coenzyme Q10 is administered prior to administration of the additional therapeutic agent.

7. The method of claim 4 , wherein the Coenzyme Q10 is administered subsequent to administration of the additional therapeutic agent.

8. The method of claim 4 , wherein the additional therapeutic agent is a chemotherapeutic agent.

9. The method of claim 8 , wherein the chemotherapeutic agent is gemcitabine.